RxDoctor Payments Data

Julianne Folsom

Psychiatric/Mental Health · Tallahassee, FLNPI 1629691225

Payments from drug & device makers

$10,320in general payments, 2019–2025

Across 180 payments — averaging $57.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Almatica Pharma LLC$7K
  • AbbVie$528
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$376
  • Johnson & Johnson$315
  • Otsuka America Pharmaceutical, Inc.$310
  • Takeda Pharmaceuticals U.S.A., Inc.$280
  • plus $1K from 17 others

What the payments were for

  • Speaking & faculty fees$6,60064%
  • Food & beverage$3,53934%
  • Education$1812%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,320 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$36,866
Medicare patients
62
Services billed
364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole14$43,218
RexultiBrexpiprazole21$38,285
TrintellixVortioxetine Hydrobromide16$16,293
Chlorpromazine Hcl11$1,853
Divalproex Sodium ErDivalproex Sodium21$1,675
Quetiapine Fumarate59$1,589
Fluphenazine Decanoate12$1,081
Olanzapine26$976
Gabapentin53$926
Clonazepam64$923
Bupropion XlBupropion Hcl15$538
Divalproex Sodium11$534
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine19$484
Memantine Hcl21$472
Risperidone15$406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$310$81,50235 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$280$16,29316 claims
Almatica Pharma LLCSertraline Hcl$7,017$3412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →